176 related articles for article (PubMed ID: 34819728)
1. Targeted Nanotherapeutics Using LACTB Gene Therapy Against Melanoma.
Liu J; Yang L; Yuan X; Xiong M; Zhu J; Wu W; Ren M; Long J; Xu X; Gou M
Int J Nanomedicine; 2021; 16():7697-7709. PubMed ID: 34819728
[TBL] [Abstract][Full Text] [Related]
2. Targeted nanoparticle-mediated LHPP for melanoma treatment.
Zhang Q; Xiong M; Liu J; Wang S; Du T; Kang T; Liu Y; Cheng H; Huang M; Gou M
Int J Nanomedicine; 2019; 14():3455-3468. PubMed ID: 31190803
[No Abstract] [Full Text] [Related]
3. LACTB suppresses melanoma progression by attenuating PP1A and YAP interaction.
Ma Y; Wang L; He F; Yang J; Ding Y; Ge S; Fan X; Zhou Y; Xu X; Jia R
Cancer Lett; 2021 May; 506():67-82. PubMed ID: 33675985
[TBL] [Abstract][Full Text] [Related]
4. LACTB, a novel epigenetic silenced tumor suppressor, inhibits colorectal cancer progression by attenuating MDM2-mediated p53 ubiquitination and degradation.
Zeng K; Chen X; Hu X; Liu X; Xu T; Sun H; Pan Y; He B; Wang S
Oncogene; 2018 Oct; 37(41):5534-5551. PubMed ID: 29899406
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effect of iRGD-modified liposomes containing conjugated linoleic acid-paclitaxel (CLA-PTX) on B16-F10 melanoma.
Du R; Zhong T; Zhang WQ; Song P; Song WD; Zhao Y; Wang C; Tang YQ; Zhang X; Zhang Q
Int J Nanomedicine; 2014; 9():3091-105. PubMed ID: 25028548
[TBL] [Abstract][Full Text] [Related]
6. The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation.
Yu KF; Zhang WQ; Luo LM; Song P; Li D; Du R; Ren W; Huang D; Lu WL; Zhang X; Zhang Q
Int J Nanomedicine; 2013; 8():2473-85. PubMed ID: 23885174
[TBL] [Abstract][Full Text] [Related]
7. Potential anticancer properties of the water extract of Inonotus [corrected] obliquus by induction of apoptosis in melanoma B16-F10 cells.
Youn MJ; Kim JK; Park SY; Kim Y; Park C; Kim ES; Park KI; So HS; Park R
J Ethnopharmacol; 2009 Jan; 121(2):221-8. PubMed ID: 19041933
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor effect of adenovirus-mediated gene transfer of pigment epithelium-derived factor on mouse B16-F10 melanoma.
Yang LP; Cheng P; Peng XC; Shi HS; He WH; Cui FY; Luo ST; Wei YQ; Yang L
J Exp Clin Cancer Res; 2009 Jun; 28(1):75. PubMed ID: 19500366
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of LACTB, a Mitochondrial Protein That Inhibits Proliferation and Invasion in Glioma Cells.
Li HT; Dong DY; Liu Q; Xu YQ; Chen L
Oncol Res; 2019 Mar; 27(4):423-429. PubMed ID: 28835318
[TBL] [Abstract][Full Text] [Related]
10. LACTB induces cancer cell death through the activation of the intrinsic caspase-independent pathway in breast cancer.
Gonzalez-Morena JM; Escudeiro-Lopes S; Ferreira-Mendes JM; Jakoube P; Cutano V; Vinaixa-Forner J; Kralova Viziova P; Hartmanova A; Sedlacek R; Machado S; Malcekova B; Keckesova Z
Apoptosis; 2023 Feb; 28(1-2):186-198. PubMed ID: 36282364
[TBL] [Abstract][Full Text] [Related]
11. LACTB promotes metastasis of nasopharyngeal carcinoma via activation of ERBB3/EGFR-ERK signaling resulting in unfavorable patient survival.
Peng LX; Wang MD; Xie P; Yang JP; Sun R; Zheng LS; Mei Y; Meng DF; Peng XS; Lang YH; Qiang YY; Li CZ; Xu L; Liu ZJ; Guo LL; Xie DH; Shu DT; Lin ST; Luo FF; Huang BJ; Qian CN
Cancer Lett; 2021 Feb; 498():165-177. PubMed ID: 33152401
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of monomethoxy poly(ethylene glycol)-poly (ε-caprolactone) micelle-encapsulated doxorubicin against mouse melanoma.
Zheng L; Gou M; Zhou S; Yi T; Zhong Q; Li Z; He X; Chen X; Zhou L; Wei Y; Qian Z; Zhao X
Oncol Rep; 2011 Jun; 25(6):1557-64. PubMed ID: 21455590
[TBL] [Abstract][Full Text] [Related]
13. Regression of established subcutaneous B16-F10 murine melanoma tumors after gef gene therapy associated with the mitochondrial apoptotic pathway.
Prados J; Melguizo C; Ortiz R; Boulaiz H; Carrillo E; Segura A; Rodríguez-Herva JJ; Ramos JL; Aránega A
Exp Dermatol; 2010 Apr; 19(4):363-71. PubMed ID: 19645856
[TBL] [Abstract][Full Text] [Related]
14. PCBP1 protects bladder cancer cells from mitochondria injury and ferroptosis by inducing LACTB mRNA degradation.
Luo Y; Zhang Y; Pang S; Min J; Wang T; Wu D; Lin C; Xiao Z; Xiang Q; Li Q; Ma L
Mol Carcinog; 2023 Jul; 62(7):907-919. PubMed ID: 37157950
[TBL] [Abstract][Full Text] [Related]
15. Investigation of the biological effects of anti-cell adhesive synthetic peptides that inhibit experimental metastasis of B16-F10 murine melanoma cells.
Humphries MJ; Yamada KM; Olden K
J Clin Invest; 1988 Mar; 81(3):782-90. PubMed ID: 3343338
[TBL] [Abstract][Full Text] [Related]
16. Forsythiae Fructus Inhibits B16 Melanoma Growth Involving MAPKs/Nrf2/HO-1 Mediated Anti-Oxidation and Anti-Inflammation.
Bao J; Ding R; Zou L; Zhang C; Wang K; Liu F; Li P; Chen M; Wan JB; Su H; Wang Y; He C
Am J Chin Med; 2016; 44(5):1043-61. PubMed ID: 27430915
[TBL] [Abstract][Full Text] [Related]
17. LACTB exerts tumor suppressor properties in epithelial ovarian cancer through regulation of Slug.
Cutano V; Ferreira Mendes JM; Escudeiro-Lopes S; Machado S; Vinaixa Forner J; Gonzales-Morena JM; Prevorovsky M; Zemlianski V; Feng Y; Kralova Viziova P; Hartmanova A; Malcekova B; Jakoube P; Iyer S; Keckesova Z
Life Sci Alliance; 2023 Jan; 6(1):. PubMed ID: 36375842
[TBL] [Abstract][Full Text] [Related]
18. Synthetic phosphoethanolamine a precursor of membrane phospholipids reduce tumor growth in mice bearing melanoma B16-F10 and in vitro induce apoptosis and arrest in G2/M phase.
Ferreira AK; Meneguelo R; Marques FL; Radin A; Filho OM; Neto SC; Chierice GO; Maria DA
Biomed Pharmacother; 2012 Oct; 66(7):541-8. PubMed ID: 22902646
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor activity of N-trimethyl chitosan-encapsulated camptothecin in a mouse melanoma model.
Liu XP; Zhou ST; Li XY; Chen XC; Zhao X; Qian ZY; Zhou LN; Li ZY; Wang YM; Zhong Q; Yi T; Li ZY; He X; Wei YQ
J Exp Clin Cancer Res; 2010 Jun; 29(1):76. PubMed ID: 20565783
[TBL] [Abstract][Full Text] [Related]
20. Sodium dichloroacetate attenuates the growth of B16-F10 melanoma in vitro and in vivo: an opportunity for drug repurposing.
do Nascimento RS; Nagamine MK; De Toledo GF; Chaible LM; Tedardi MV; Del-Grande MP; da Fonseca IIM; Dagli MLZ
Anticancer Drugs; 2021 Feb; 32(2):111-116. PubMed ID: 33395068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
